Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Roniciclib in Solid Tumors
NCT02390154Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of roniciclib in solid tumor (2 arms), sponsored by Bayer. Primary endpoints: Amount of Roniciclib in urine as percentage of the dose of total radioactivity up to 336 hours, Amount of Roniciclib in feces as percentage of the dose of total radioactivity up to 336 hours and 5 more. Started Apr 2015; status: completed.
02
Drugs
roniciclib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02390154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390154.